Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity.
about
The x-ray structure of the adduct between NAMI-A and carbonic anhydrase provides insights into the reactivity of this metallodrug with proteinsHuman carbonic anhydrase II as a host for piano-stool complexes bearing a sulfonamide anchorCharacterization of a versatile organometallic pro-drug (CORM) for experimental CO based therapeuticsComplex formation between Ru(η(6)-p-cym)(H2O)3]2+ and (O,O) donor ligands with biological relevance in aqueous solution.Ruthenium polypyridyl complex inhibits growth and metastasis of breast cancer cells by suppressing FAK signaling with enhancement of TRAIL-induced apoptosis.Vanadium speciation by XANES spectroscopy: a three-dimensional approach.Reactivity-activity relationships of oral anti-diabetic vanadium complexes in gastrointestinal media: an X-ray absorption spectroscopic study.Biotransformations of Antidiabetic Vanadium Prodrugs in Mammalian Cells and Cell Culture Media: A XANES Spectroscopic Study.Comparison of KP1019 and NAMI-A in tumour-mimetic environments.X-ray fluorescence microscopy for investigation of archival tissues.Developing drug molecules for therapy with carbon monoxide.The use of X-ray absorption and synchrotron based micro-X-ray fluorescence spectroscopy to investigate anti-cancer metal compounds in vivo and in vitro.Interactive association of drugs binding to human serum albumin.Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.Arene ruthenium(ii) complex, a potent inhibitor against proliferation, migration and invasion of breast cancer cells, reduces stress fibers, focal adhesions and invadopodia.X-ray fluorescence imaging of single human cancer cells reveals that the N-heterocyclic ligands of iodinated analogues of ruthenium anticancer drugs remain coordinated after cellular uptake.Self-assembled metalla-rectangles bearing azodipyridyl ligands: synthesis, characterization and antitumor activity.Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells.Promising anticancer mono- and dinuclear ruthenium(III) dithiocarbamato complexes: systematic solution studies.Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy.Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse.X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019).Photo-induced cytotoxicity and anti-metastatic activity of ruthenium(ii)-polypyridyl complexes functionalized with tyrosine or tryptophan.Binding and Anticancer Properties of Plumbagin with Human Serum Albumin.HSA IIA subdomain-based developing anticancer metal prodrug: a new and improved approach.Antiangiogenic ruthenium(ii) benzimidazole complexes, structure-based activation of distinct signaling pathways.Simultaneous observation of the metabolism of cisplatin and NAMI-A in human plasma in vitro by SEC-ICP-AES.X-ray absorption spectroscopy studies of the adducts formed between cytotoxic gold compounds and two major serum proteins.Ruthenium (II) polypyridyl complexes stabilize the bcl-2 promoter quadruplex and induce apoptosis of Hela tumor cells.Synthesis and Characterization of -Dichlorotetrakis(imidazole)cobalt(III) Chloride: A New Cobalt(III) Coordination Complex with Potential Prodrug Properties
P2860
Q27664948-E932B7FA-8B3B-41E9-9E50-BB669274ACBDQ27670566-D2CBECDF-185E-4D8D-9DC1-71FBBE861E23Q27675422-255CD345-5C0A-46CA-A5CD-7290F759EE6EQ33710620-06C4AF3D-1629-45C6-83FF-C8DA949615C0Q35183003-EA31F568-2CC2-46D5-AA9C-6ED05236AFC5Q35218165-F18ACA6C-A27F-4449-9D53-E1BA4F4EFAF3Q35220583-F3D7580B-6830-458D-915F-CBBF8DE35B23Q35612899-570FCEB8-E3A3-4336-96F4-F526CC8FC7A5Q36086603-F5B3E3CA-3C8B-4E2C-B9AB-361C597F38B4Q37027428-B4A2A193-20C9-4F6A-AD4F-42EB3D65678AQ37986364-34C837C4-F24A-4295-801D-9E5D284CADA3Q38096196-9BA7BE1A-7499-4100-A389-2F782EFA73A4Q38192435-C988D250-5F6A-4CC0-9348-7FCE91637264Q38930683-F3494D87-E5E3-479B-A404-ED5850315EBDQ38964287-0B923CB0-1300-4326-BC1E-45660591D054Q39110547-F9A81D66-D165-4813-BE18-C1998CDCA2E0Q39257995-5A3A68DA-5E1A-467C-AD23-5A25DCC95BADQ39294174-0704D275-88F8-402F-A4E4-982A94AF490CQ39463198-89629BEA-9F0A-49B6-8CEF-8FA2A1A4B49AQ40737623-76463792-3DFF-4603-97A7-08D53F61256BQ41883625-95534109-98A3-48CF-9511-897A8E13366DQ43242098-9749953B-23D1-49AF-9C15-B5F5C0596F84Q46371577-10EA2E76-C757-4400-867C-CEA8015785E2Q46795399-CEA851DF-A548-42E0-BBD1-620F9A41CDC5Q48235169-D5A08D85-7E34-4B74-97E1-2C7C8D23A4F0Q51013825-88F5B433-39D0-44B8-8E31-32BB1B13C513Q51756809-5EB1D902-E5C6-4524-9C83-56BD9DAF67F0Q53280829-CEEA1FE1-757B-4CFF-BC48-5A0F7ED572FEQ54265966-7ACF04F2-03DA-49DB-8D73-A82623D7B690Q58766793-C1314545-0B19-4209-84BD-075D75DBDE6F
P2860
Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Characterization of a ruthenium
@nl
Characterization of a rutheniu ...... high anti-metastatic activity.
@en
type
label
Characterization of a ruthenium
@nl
Characterization of a rutheniu ...... high anti-metastatic activity.
@en
prefLabel
Characterization of a ruthenium
@nl
Characterization of a rutheniu ...... high anti-metastatic activity.
@en
P2093
P2860
P356
P1476
Characterization of a rutheniu ...... high anti-metastatic activity.
@en
P2093
Aviva Levina
Yee Yen Gwee
Zhi Jun Lim
P2860
P304
P356
10.1002/ANIE.200906079
P407
P50
P577
2010-02-01T00:00:00Z